Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration

摘要: To report a series of age-related macular degeneration (AMD) patients in whom progression to geographic atrophy (GA) in one eye receiving frequent intravitreal injections anti-vascular endothelial growth factor (anti-VEGF) therapy for type 1 neovascularization (NV) was slower than that the fellow with non-neovascular AMD. Retrospective, observational case examining clinical course and GA rate four consecutive which one harbored 1 neovascular AMD was receiving anti-VEGF therapy, while manifested signs non-neovascular AMD only. Eligibility criteria included anti-VEGF duration over 4 years 50 injections. Lesion evolution documented via multimodal imaging. at baseline final visits quantified each was determined. Four were followed mean interval 94 months (range 62–120). One NV remained non-neovascular. The former received 65.5 ± 15.2 Mean non-neovascular eyes 0.076 ± 0.024 mm2/month 0.004 ± 0.005 mm2/month. Difference between non-neovascular eyes found be statistically significant (P = 0.001). These findings support previous hypotheses that, unlike 2 3 lesions, may represent subtype more resilient to GA formation. This have implications regimens management NV.